Ocugen to Present Modifier Gene Therapy Platform at Three Major June Industry Conferences

Ocugen, Inc. has scheduled presentations at three key investor and industry events in June 2026 to showcase its advancements in gene therapy for blindness. The company will participate in the Noble Capital Markets Emerging Growth Virtual Equity Conference, Clinical Trials at the Summit 2026, and the BIO International Convention. These appearances represent a strategic effort to engage the investment community and industry peers following significant clinical milestones and recent financial restructuring.

Ocugen, Inc. (NASDAQ: OCGN), a Malvern-based biotechnology firm, announced its participation in a series of high-level industry events throughout June 2026 to present its modifier gene therapy platform. The company is slated to appear at the Noble Capital Markets Emerging Growth Virtual Equity Conference, which will include a webcast accessible via the company’s investor relations portal. Ocugen will also maintain a presence at Clinical Trials at the Summit 2026 and the BIO International Convention. These events serve as vital platforms for the company to detail its gene-agnostic approach to treating complex blindness diseases, which differs from traditional gene editing by addressing entire gene networks rather than single gene mutations.

The presentations will focus on Ocugen’s clinical pipeline, including treatments for retinitis pigmentosa, Stargardt disease, and geographic atrophy (GA). Recent data highlights that the company will likely discuss include a 31% reduction in GA lesion growth observed in OCU410 trials and the completion of enrollment for OCU400 and OCU410ST trials. By utilizing these conferences to share such technical data, Ocugen aims to demonstrate the efficacy of its platform to a broad audience of clinicians and potential partners. The company’s participation highlights the ongoing role of specialized industry conferences in the dissemination of late-stage clinical trial results.

Financially, the conference circuit follows a period of intense capital management for Ocugen, including the issuance of up to $130 million in 6.75% Convertible Senior Notes due 2034. This move was designed to repay existing debt and extend the company's operational cash runway through 2028. Despite the strategic importance of these visibility events, the market reaction to the announcement was a 2.19% decline in stock price, reflecting broader volatility in the biotech sector. For the Events & Conferences market, Ocugen’s commitment to a mix of virtual and in-person industry gatherings underscores the sector's necessity for facilitating high-stakes investor relations and scientific exchange.